Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases

被引：5

作者：

Sadraeian, Mohammad ^{[1
]}

Maleki, Reza ^{[2
]}

Moraghebi, Mahta ^{[2
]}

Bahrami, Abasalt ^{[3
]}

机构：

[1] Univ Technol Sydney, Inst Biomed Mat & Devices IBMD, Fac Sci, Sydney, NSW 2007, Australia

[2] Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5005, Australia

[3] Univ Calif Los Angeles, Dept Chem & Biochem Bioengn & Mat Sci & Engn, Los Angeles, CA 90095 USA

来源：

MOLECULES | 2024年 / 29卷 / 13期

关键词：

phage display; biopanning; diagnosis; therapeutic applications; CELL LUNG-CANCER; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; OPEN-LABEL; RECOMBINANT ANTIBODIES; RHEUMATOID-ARTHRITIS; 1ST-LINE THERAPY; PEPTIDES;

D O I：

10.3390/molecules29133002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In recent years, phage display technology has become vital in clinical research. It helps create antibodies that can specifically bind to complex antigens, which is crucial for identifying biomarkers and improving diagnostics and treatments. However, existing reviews often overlook its importance in areas outside cancer research. This review aims to fill that gap by explaining the basics of phage display and its applications in detecting and treating various non-cancerous diseases. We focus especially on its role in degenerative diseases, inflammatory and autoimmune diseases, and chronic non-communicable diseases, showing how it is changing the way we diagnose and treat illnesses. By highlighting important discoveries and future possibilities, we hope to emphasize the significance of phage display in modern healthcare.

引用

页数：22

共 152 条

[1] Isolation of soluble scFv antibody fragments specific for small biomarker molecule, L-Carnitine, using phage display [J].

Abou El-Magd, Rabab M. ;

Vozza, Nicolas F. ;

Tuszynski, Jack A. ;

Wishart, David S. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2016, 428 :9-19

[2] Phage display as a promising approach for vaccine development [J].

Aghebati-Maleki, Leili ;

Bakhshinejad, Babak ;

Baradaran, Behzad ;

Motallebnezhad, Morteza ;

Aghebati-Maleki, Ali ;

Nickho, Hamid ;

Yousefi, Mehdi ;

Majidi, Jafar .

JOURNAL OF BIOMEDICAL SCIENCE, 2016, 23

[3] Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display [J].

Araujo, Galber Rodrigues ;

Vaz, Emilia Rezende ;

Fujimura, Patricia Tiemi ;

Fonseca, Joao Eurico ;

de Lima, Lucelia Maria ;

Canhao, Helena ;

Venturini, Gabriela ;

Morais Cardozo, Karina Helena ;

Carvalho, Valdemir Melechco ;

Napimoga, Marcelo Henrique ;

Goulart, Luiz Ricardo ;

Goncalves, Joao ;

Ueira-Vieira, Carlos .

ARTHRITIS RESEARCH & THERAPY, 2015, 17

[4] SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB [J].

Avery, Robert L. ;

Castellarin, Alessandro A. ;

Steinle, Nathan C. ;

Dhoot, Dilsher S. ;

Pieramici, Dante J. ;

See, Robert ;

Couvillion, Stephen ;

Nasir, Ma'an A. ;

Rabena, Melvin D. ;

Maia, Mauricio ;

Van Everen, Sherri ;

Le, Kha ;

Hanley, William D. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (10) :1847-1858

[5] Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer [J].

Aydin, Ahmet Murat ;

Woldu, Solomon L. ;

Hutchinson, Ryan C. ;

Boegemann, Martin ;

Bagrodia, Aditya ;

Lotan, Yair ;

Margulis, Vitaly ;

Krabbe, Laura-Maria .

ONCOTARGETS AND THERAPY, 2017, 10 :1487-1502

[6]

Azevedo A, 2017, ACTAS DERMO-SIFILOGR, V108, P305, DOI 10.1016/j.ad.2016.09.021

[7] Phage display technology: clinical applications and recent innovations [J].

Azzazy, HME ;

Highsmith, WE .

CLINICAL BIOCHEMISTRY, 2002, 35 (06) :425-445

[8] Phage display biopanning and isolation of target-unrelated peptides: in search of nonspecific binders hidden in a combinatorial library [J].

Bakhshinejad, Babak ;

Zade, Hesam Motaleb ;

Shekarabi, Hosna Sadat Zahed ;

Neman, Sara .

AMINO ACIDS, 2016, 48 (12) :2699-2716

[9] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[10] Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis [J].

Banerji, A. ;

Busse, P. ;

Shennak, M. ;

Lumry, W. ;

Davis-Lorton, M. ;

Wedner, H. J. ;

Jacobs, J. ;

Baker, J. ;

Bernstein, J. A. ;

Lockey, R. ;

Li, H. H. ;

Craig, T. ;

Cicardi, M. ;

Riedl, M. ;

Al-Ghazawi, A. ;

Soo, C. ;

Iarrobino, R. ;

Sexton, D. J. ;

TenHoor, C. ;

Kenniston, J. A. ;

Faucette, R. ;

Still, J. G. ;

Kushner, H. ;

Mensah, R. ;

Stevens, C. ;

Biedenkapp, J. C. ;

Chyung, Y. ;

Adelman, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08) :717-728

← 1 2 3 4 5 6 7 8 9 10 →